Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

A New Multi-center, Randomized, Double-blind, Placebo-controlled Canine Study Confirms NEM® Brand Eggshell Membrane is an Effective Joint Treatment for Man's Best Friend

Stratum Nutrition
Posted on: 23 Aug 16

PR Newswire

CARTHAGE, Mo., Aug. 23, 2016

CARTHAGE, Mo., Aug. 23, 2016 /PRNewswire/ -- Stratum Nutrition and joint-venture partner, ESM Technologies, the manufacturer of innovative, commercialized eggshell and eggshell membrane wellness ingredients, are pleased to announce a new canine study has published in the journal, Veterinary Medicine: Research & Reports, evaluating their joint health ingredient, NEM® brand eggshell membrane.

This 6-week, multi-center, randomized, double-blind, placebo-controlled trial was conducted at eight different veterinary clinics to evaluate NEM's efficacy, safety and tolerability in the treatment of sub-optimal joint function in dogs. Fifty-one privately-owned dogs having mild to moderate persistent sub-optimal joint function (e.g. difficulty in getting up from a laying position, a noticeable limp, impaired gait, difficulty in climbing stairs, etc.) received either oral NEM®, 6 mg/lb. (~13.5 mg/kg) or placebo once daily for 6 weeks. Changes in joint function, joint pain, and quality of life in the NEM® group versus the placebo group were evaluated by both dog owners and veterinarians via either the validated Canine Brief Pain Inventory (CBPI) (owner assessment, 1 week & 6 weeks) or Veterinary Canine Scoring Assessments (VCSA) (veterinarian assessments, 6 weeks). Additionally, changes in serum levels of the cartilage degradation biomarker, CTX-II, were also evaluated at 6 weeks. 

Results showed that supplementation with NEM® significantly reduced joint pain and improved joint function rapidly (CBPI 1-week) and demonstrated a lasting improvement in joint pain (VCSA 6-week) leading to an improved quality of life (CBPI 6-week). Moreover, a profound chondroprotective effect was demonstrated following 6 weeks of supplementation with NEM® (CTX-II). There were also clinically meaningful results from a brief responder analysis, demonstrating that a significant proportion of treated dogs will benefit substantially from NEM® supplementation. The results of this peer-reviewed study were recently published online (

"This canine study on NEM® provides further evidence supporting NEM's ability to modify symptoms of pain, and it provides an alternative to the use of pharmaceuticals," mentioned Kenneth J. Kopp, DVM, the lead veterinarian for the trial.  

Kevin J. Ruff Ph.D., MBA, CCRP – Sr. Director of Scientific & Regulatory Affairs for Stratum Nutrition – also commented on the study, "It was particularly gratifying to learn of the chondroprotective effect in this study, as we believe this to be the first of its kind in naturally-occurring joint disease in dogs."

For more information, please visit


To view the original version on PR Newswire, visit:

SOURCE Stratum Nutrition

PR Newswire

Last updated on: 23/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.